IL142054A0 - Oral dosage formulations comprising (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid - Google Patents

Oral dosage formulations comprising (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid

Info

Publication number
IL142054A0
IL142054A0 IL14205499A IL14205499A IL142054A0 IL 142054 A0 IL142054 A0 IL 142054A0 IL 14205499 A IL14205499 A IL 14205499A IL 14205499 A IL14205499 A IL 14205499A IL 142054 A0 IL142054 A0 IL 142054A0
Authority
IL
Israel
Prior art keywords
morpholinol
difluorophenyl
dimethyl
alginic acid
oral dosage
Prior art date
Application number
IL14205499A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL142054A0 publication Critical patent/IL142054A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14205499A 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid IL142054A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28
PCT/EP1999/007117 WO2000018406A1 (en) 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid

Publications (1)

Publication Number Publication Date
IL142054A0 true IL142054A0 (en) 2002-03-10

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14205499A IL142054A0 (en) 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid

Country Status (17)

Country Link
EP (1) EP1117407A1 (xx)
JP (1) JP2002525328A (xx)
KR (1) KR20010075385A (xx)
CN (1) CN1328459A (xx)
AR (1) AR022673A1 (xx)
AU (1) AU6087399A (xx)
BR (1) BR9914096A (xx)
CA (1) CA2345638A1 (xx)
CZ (1) CZ20011142A3 (xx)
HU (1) HUP0103459A2 (xx)
IL (1) IL142054A0 (xx)
MA (1) MA26693A1 (xx)
NO (1) NO20011555D0 (xx)
PE (1) PE20001087A1 (xx)
PL (1) PL346877A1 (xx)
TR (1) TR200100863T2 (xx)
WO (1) WO2000018406A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
NO20011555L (no) 2001-03-27
TR200100863T2 (tr) 2001-07-23
MA26693A1 (fr) 2004-12-20
KR20010075385A (ko) 2001-08-09
CN1328459A (zh) 2001-12-26
NO20011555D0 (no) 2001-03-27
CZ20011142A3 (cs) 2001-09-12
PL346877A1 (en) 2002-03-11
WO2000018406A1 (en) 2000-04-06
JP2002525328A (ja) 2002-08-13
AR022673A1 (es) 2002-09-04
BR9914096A (pt) 2001-07-31
PE20001087A1 (es) 2000-10-20
HUP0103459A2 (hu) 2002-01-28
EP1117407A1 (en) 2001-07-25
AU6087399A (en) 2000-04-17
CA2345638A1 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
CA2355854A1 (en) Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
AU2317699A (en) Dental restoratives
HUP0100950A3 (en) Cyclic amino compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
HUP0104195A3 (en) Vitamin d analogues, preparation thereof, pharmaceutical and cosmetic compositions containing them
IL172695A0 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
AU4338099A (en) Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient
AU3216600A (en) Analgesic compositions comprising anti-epileptic compounds and methods of using same
HUP0103464A3 (en) Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them
HUP0203505A3 (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, and pharmaceutical compositions containing said compounds
AU1574900A (en) Pharmaceutical compositions containing insulin
HU9802795D0 (en) Pharmaceutical compositions containing more active components
HUP0103924A3 (en) Oral pharmaceutical compositions containing buprenorphin
HUP0105204A3 (en) Substituted phenethylamine derivatives and pharmaceutical compositions containing them
IL142534A0 (en) Pharmaceutical compositions containing an antigen-adjuvent
PL349393A1 (en) Sulphonyloxazolamines as therapeutic active ingredients
AU1453600A (en) Solid oral dosage forms containing alginic acid and famotidine
IL142054A0 (en) Oral dosage formulations comprising (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid
ZA997511B (en) Novel heteroethynlene compounds and pharmaceutical and cosmetic compositions containing same.
HUP9800413A3 (en) Fungicide composition containing 5-methyl-5-(4-phenoxyphenyl)-3-phenylamino-2,4-oxazolidinedione and triazole-derivative compound as active ingredients and use thereof
HU9802716D0 (en) Pharmaceutical composition of analgesic activity
IL138994A0 (en) 2-methylpropionic acid derivatives and medicinal compositions containing the same
AU6524298A (en) Pharmaceutical composition, containing medium-chain fatty acids as active ingredients, for dental caries and periodontal disease
HU9800623D0 (en) Oral application of "(+)-o-demethyl-tramadol as analgesic active component
HU9502509D0 (en) Use of 1,4-dihydropyridine-3,5-dicarboxylic-acid-esters as active component of pharmaceutical compositions